Title: An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
1260092-44-1
1365655-91-9
756525-91-4
882847-13-4
1347750-75-7
1347750-78-0
2182601-72-3 | Cy5 DBCO | AA019ECR | MFCD31536766
2183440-65-3 | FAM hydrazide, 6-isomer | AA019EGK | MFCD31580090
1013573-81-3 | 4-bromo-N-(2-chloro-4-methylphenyl)benzenesulfonamide | AA019EJU | MFCD10170248
51166-20-2 | 15-Methylhexadecan-1-ol | AA019EN2 | MFCD31652808
256664-96-7 | Methyl 2-ethyl-6-methoxybenzoate | AA019EQJ | MFCD18904851
1431434-22-8 | Ethyl (5-Bromo-2-(6-Fluoronicotinoyl)Benzofuran-3-Yl)(3-Methoxypropyl)Carbamate | AA019ET2 | MFCD30471769
1823872-01-0 | tert-butyl 2-amino-4-formylthiazole-3(2H)-carboxylate | AA019EWF | MFCD22631565
1460321-45-2 | (R)-2-(1-Hydroxyethyl)pyrimidin-5-ol | AA019EZQ | MFCD28096707
643-22-1 | Erythromycin stearate | AA019FSX | MFCD00084690
1629857-89-1 | 2-[(4-chlorophenyl)formamido]-3-methylbutanoic acid | AA019GEF | MFCD02914671